Two European Marijuana Companies Team Up To Bring Cannabis-Based Solutions To Poland
SOMAÍ Pharmaceuticals, a Portugal-headquartered marijuana company has partnered with Cosma S.A., a Poland-based company focused on cannabis-based pharmaceutical advancements. Under this strategic partnership, Cosma is designated as the marketing authorization holder (MAH) for both Cosma and SOMAÍ’s cannabis-based products.
“Through partnering with Cosma, we are dedicated to improving Polish patients’ access with the highest-quality innovative, improved performance and tasting solutions that have the potential to change their lives for the better,” stated Michael Sassano, founder and interim CEO of SOMAÍ Pharmaceuticals. “SOMAÍ has the largest range of extracted innovative products with over 100+ stabilized EU-GMP products, and looks forward to introducing the Polish doctors and patients to many more advanced therapies and choices to help them.”
Cosma S.A. and SOMAÍ will introduce a range of advanced cannabis-based product lines to Polish patients, including various formulations of purified oral solutions and inhalation extracts. SOMAÍ noted that the oral solution’s formula is based on purified full-spectrum cannabis extract that combines a variety of THC/CBD ratios, genetics and formulations with different terpene as well as flavonoid options to cover a wide range of medical conditions. Oral solutions and inhalation extracts are available in three specialized lines: Essentials, Origins and Senses.
Read Also: Most Important Medical Potential Of Marijuana? Cannabis For Pain Relief Says Biotech CEO
These single-strain products …